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Reply
Dear Sir:
We thank Doctors Eriksson, Friedman, Cushner, and
Lassen for their letter regarding our recently published
manuscript: Potent anticoagulants are associated with a
higher all-cause mortality rate after hip and knee arthro-
plasty [15].
They have challenged the evidence presented in our
paper which suggests that potent anticoagulants are
associated with higher mortality than multimodal throm-
boprophylaxis by raising numerous issues related to the
selection, analysis, and presentation of the data. Unfortu-
nately they did not address the core messages of our paper
which were: (1) that pulmonary emboli occur despite the
use of potent anticoagulants; and (2) that these agents have
never been shown to reduce mortality.
(1) Eriksson et al. challenged our decision of including
different potent anticoagulants in Group A, arguing
that all anticoagulants are not equivalent. Although
anticoagulants may have different mechanisms of
action, the all-cause mortality with these different
drugs seems similar, none seemed to eliminate
pulmonary emboli, and they all share the same
unwanted bleeding risk. The all-cause mortality in
the Group C (patients receiving warfarin alone) was
no different than in Group A (patients receiving
potent anticoagulants alone). Until someone can show
that one of these anticoagulants results in lower all-
cause mortality than another, one must assume they
all carry the same risk.
(2) They questioned the quality and consistency of the
data in the different groups: In Groups B (multimodal
thromboprophylaxis with preferred use of aspirin) and
C, there are some cohort studies, and some using
‘‘intention to treat’’; whereas the majority of Group A
studies (potent anticoagulants) were drug-industry
sponsored randomized trials. Eriksson et al. assumed
that randomized trials provide more robust data thus
explaining the difference in mortality between the
groups. However, in the majority of these randomized
trials, patients were excluded for various reasons
including thrombocytopenia, renal insufficiency, or
bilateral surgery. Cohort studies include these patients
who are at greater risk of adverse outcomes. The two-
cohort trial of patients in Group A had an all-cause
mortality rate of 0.61% (16 of 2629) [10, 11], whereas
the randomized studies had a rate of 0.36% (44 of
12121). This suggests that the risk of using powerful
anticoagulants in the general population may be even
greater than suggested from randomized trials.
(3) Eriksson et al. pointed out that we incorrectly cited the
study by Lachiewicz et al. [8] as being a prospective
cohort rather than a randomized trial. It was indeed a
randomized trial of two types of pneumatic compres-
sion devices. However, as all patients received
multimodal thromboprophylaxis, we thought it more
appropriate to designate them as a prospective cohort
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as they were not randomized to the pharmacologic
agents being evaluated in our review.
(4) They mentioned that we included two deaths in the
so-called ‘‘placebo group’’ from the study by Heit
et al. [7]. Their statement is incorrect. In that study,
all patients received potent anticoagulation during
their hospital stay. At discharge they were random-
ized to receive a placebo or continue with potent
anticoagulation. All patients in the study, including
those in the placebo group received potent anticoag-
ulation for 4 to 10 days during their hospital stay.
(5) Eriksson et al. stated that the diagnosis of pulmonary
embolism in our study is not based in a central,
blinded adjudication of outcome. This is correct. The
diagnosis of a pulmonary embolus was adjudicated
based on the information in each publication. As we
stated in our article [15], one of our major goals was
to introduce and use the concept of all-cause mortality
that encompasses all benefits and complications of
thromboprophylaxis. No central, blinded adjudication
of the outcome ‘‘death’’ is needed.
(6) They also stated there is ‘‘significant heterogeneity’’
in mortality rates between the various Group A
studies, ranging from 0% to 0.62%, which invalidates
any of our conclusions. The 0% rate involved the
smallest cohorts that included 104, 132, and 643
patients in Group A, and 100 and 200 patients in
Group B. Sample size accounts for much of the
variance. The other variable is length of followup (6
vs. 12 weeks). In addition, they state that ‘‘two of the
studies in Group A (potent anticoagulant group)
completed enrollment by 1996 and were unlikely to
be representative of modern practice’’. However,
Lassen et al. [9] and Geerts et al. [6] cited rates of
fatal pulmonary embolism from the 1960s and 1970s
[5] to justify the current use of potent anticoagulants
(‘‘Some deep-vein thromboses embolize, resulting in
a pulmonary embolism that is fatal in 0.1–0.4% of
unprotected patients’’ [5].)
(7) Of most importance to Eriksson et al. is the argument
that our study did not address the compelling
arguments for anticoagulant-based thromboprophy-
laxis set forth by Geerts et al. in the ACCP Guidelines
[6]. The majority of the so-called ‘‘evidence based’’
information, is in fact derived from pharmaceutical
industry sponsored trials that use DVT on venography
as the primary end point. We acknowledge that this is
relevant but nevertheless a surrogate end point. The
lack of evidence that ‘‘pharmacologic thrombopro-
phylaxis’’ has never been shown to reduce mortality is
not addressed in the ACCP Guidelines [6]. Our study
suggests that mortality may even be increased with
these drugs. A new approach to guidelines for
thromboprophylaxis following joint replacement sur-
gery obviously is needed.
The concern of the orthopaedic community [1–3, 12, 14]
has resulted in the AAOS forming a panel of experts. They
recently released the AAOS guidelines for prevention of
thromboembolism following THA and TKA [13]. They
focus on the stratification of patients based on the risks of
venous thromboembolism and bleeding. The end points of
the guidelines include symptomatic PE and all-cause
mortality. As a consequence of a detailed analysis of the
literature, the use of aspirin for pharmacologic prophylaxis
is contemplated when patients have a standard venous
thromboembolism risk or a high risk of bleeding, and the
use of regional anesthesia is encouraged. The guidelines
will allow orthopaedic surgeons to use the pharmacologic
prophylaxis that they feel more comfortable with, without
the need to prescribe potent anticoagulants owing to fear of
potential litigation.
Our study has limitations that were discussed exten-
sively in the manuscript. Still, based on the available
information it seems reasonable to believe that the use of
potent anticoagulation may increase all-cause mortality
regardless of the beneficial effect in the rate of DVT.
Finally, we have no conflict of interest to declare. None
of us have received funding from pharmaceutical compa-
nies relating to thromboembolic disease, consulting fees
from pharmaceutical companies, nor testified as expert
witnesses in cases related to venous thromboembolism [4].
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